Company intelligence / Profile preview

Innovative Therapies

Rockville, Maryland, United Statesictbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

ICT’s lead program, GCC19CART, has shown promising results in relapsed/refractory metastatic colorectal cancer (mCRC), with a reported objective response rate (ORR) of up to 80% at higher dose levels and median overall survival exceeding 17 months in early US trials. The company’s CoupledCAR® platform aims to overcome the challenges of CAR-T therapy for solid tumors. Additional pipeline candidates are being developed for other solid tumor indications such as prostate cancer[1][2].

Therapeutic areas: OncologyPsychiatry
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on Innovative Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovative Therapies.